drugset / Trial / NCT03926013
A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The main purpose of this study are to determine the recommended Phase 2 dose (RP2D) regimen and the maximum tolerated dose, and to determine the safety of JNJ-63898081.
Timeline
- Start
- 2019-05-01
- Primary completion
- 2021-08-23
- Completion
- 2021-09-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-63898081 | Unknown | — | — |